

Divergent Nodal and Extranodal Non-Hodgkin Lymphoma Latency Patterns Following Breast Cancer by Molecular Subtype

Maryam Ali, DO • Syed Shah, MD • Khaled Elhusseiny, MD • Adnan Hajjar, MD • Ahmed Hebishy, MD
Department of Internal Medicine, East Carolina University • Greenville, North Carolina



NODAL ≠ EXTRANODAL: subtype and latency reveal two distinct post-breast cancer NHL patterns

BACKGROUND & OBJECTIVE

- Breast cancer survivors face incompletely characterized risks of subsequent lymphoid malignancy.
- Whether nodal and extranodal NHL follow distinct subtype- and latency-specific patterns remains unknown.

Do nodal and extranodal NHL demonstrate distinct latency patterns across breast cancer molecular subtypes?

METHODS

- 1

SEER Research Plus 17
2010–2022
- 2

First primary invasive breast cancer
Female patients
- 3

4 molecular subtypes
HR+/HER2+, HR-/HER2+, HR+/HER2-, HR-/HER2-
- 4

NHL presentation
Nodal vs extranodal
- 5

Latency windows
2–11 • 12–59 • 60–119 • ≥120 mo
- 6

MP–SIR methodology
Standardized incidence ratios with 95% CIs

RESULTS AT A GLANCE

